Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches

Last updated: July 14, 2025
Sponsor: University of Kansas Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pain

Pain (Pediatric)

Chronic Pain

Treatment

N/A

Clinical Study ID

NCT06582810
RKS20230063
1856VC
  • Ages > 18
  • All Genders

Study Summary

The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to:

  1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage;

  2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage;

  3. and report vasospasm prevalence in the cohort.

Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients > 18 years;

  • Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as itaccounts for patient awareness);

  • Can communicate numeric pain scores;

  • Are diagnosed with non-traumatic subarachnoid hemorrhage

Exclusion

Exclusion Criteria:

  • The patient is diagnosed with traumatic subarachnoid hemorrhage;

  • If the patient is < 18 years of age;

  • If numeric pain scores could not be captured for > 3 days of hospitalization;

  • If the patient had a prior aneurysm;

  • Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis;

  • A disability before the stroke (> 2 on modified Rankin Scale score);

  • A Hunt and Hess score > 3;

  • Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures,previous allergic reaction to lidocaine

Study Design

Total Participants: 20
Study Start date:
January 31, 2025
Estimated Completion Date:
July 31, 2028

Connect with a study center

  • Ascension Via Christi St. Francis

    Wichita, Kansas 67214
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.